<DOC>
	<DOCNO>NCT01029769</DOCNO>
	<brief_summary>The main aim trial study whether change medication non-responders two-weeks antipsychotic drug trial effective continue treatment antipsychotic . Hypothesis : Non-responders switch 2 week another antipsychotic frequently symptomatic remission week 8 non-responders stay antipsychotic</brief_summary>
	<brief_title>Efficacy Early Antipsychotic Switch Case Poor Initial Response Treatment Schizophrenia</brief_title>
	<detailed_description>The patient randomise double-blind 2 week run phase fix dose either oral amisulpride 800 mg/day olanzapine 20mg/day . Those participant respond treatment two week ( PANSS improvement &lt; 25 % ) randomise 6 week double blind flexible dose phase : 1 . Experimental intervention : switch antipsychotic ( oral olanzapine 5-20mg/d oral amisulpride 200-800 mg/d ) 2 . Control intervention : continuation drug first 2 week flexible dose range another six week Those participant respond week 2 ( ≥25 % PANSS reduction ) continue drug flexible dose range Total duration intervention per patient : 8 week</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<criteria>Inpatients DSMIV TR diagnosis schizophrenia , schizophreniform schizoaffective disorder PANSS total score baseline &gt; 75 , least two PANSS psychosis item ≥ 4 , Clinical Global Impression severity score moderately ill ( ≥4 ) Increase level care ( outpatient care day clinic inpatient care ) contraindication study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>